SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations Written by PR Newswire The specified story doesn't exist image1.jpg?p=medium600#Read more http://www.prnasia.com/story/archive/4949868_AE49868_0